Presented by

Registration online

www.henryschein.com.au/educationRegistration enquiries: Kira Field Phone: 1300 302 421 Email: events@henryschein.com.au

Lecture (Pre-requisite for workshop)

Advances in optical adjunctive aids for visualisation and detection of oral cancer and mucosal pathology.Limited to 20 participants

DATE: 10th October 2014

VENUE: The Duxton Hotel 1 St Georges Terrace, Perth WA

REGISTRATION: 8:30am

LECTURE TIME: 9.00am - 1.00pm

LECTURE COST: $85

WorkshopHands-on workshop - experience autofluorescence technology first hand. Limited to 20 participants

DATE: 10th October 2014

VENUE: Henry Schein Halas 154 Edward Street, Perth WA

WORKSHOP TIME: 1.30pm - 4.00pm

LECTURE & WORKSHOP $385

Attendance at this workshop is a pre-requisite to the purchase of Identafi from Henry Schein Halas.

Your course fee will be refunded with the purchase of Identafi.

Presented by Associate Professor Camile Farah 10th October 2014

Advances in optical adjunctive aids for visualisation and detection of oral cancer and mucosal pathology

The means for early detection is now available to all front line cliniciansThe Identafi® is intended for use by dentists, hygienists and oral surgeons as an effective tool to aid in the early detection of abnormalities that may lead to oral cancer. For oral surgeons, the Identafi® can enhance the surgeon’s ability to choose biopsy sites and aid in determining the appropriate margin of surgical incision.

Identafi® Features & Benefits• Small, compact size coupled with an angled examination mirror allows users to easily inspect hard-to-reach areas, such as under the tongue, hard and soft palate, and back of pharynx

• Space-saving design fits any treatment room

• Provides real-time information

• The combination of all three multi-spectral wavelengths provides the clinician with more relevant visual information that can aid in making treatment decisions

• Avoids need for messy, bad-tasting dyes/solutions

• Expands practice offerings

• Enhances perception of practice as the “highest standard of care”

• Dental reimbursement code (D0431) available; pays for itself in as few as 8 weeks

• The only handheld intraoral device available for cancer screening

Identafi® Ordering Information:

Identafi® System Part #RT3-00371 Disposable Mirrors Part #RT3-00105(Box of 25)

Disposable Barriers Part #RT3-00415(Box of 100)

NEW!

Multi-spectral oral cancer screeningThe deep penetrating power of the Identafi® multi-spectral fluorescence and reflectance technology enhances visualization of mucosal abnormalities such as oral cancer or premalignant dysplasia that may not be apparent to the naked eye. Unlike other fluorescence technologies and dye systems, the Identafi® is multi-spectral, with three distinct color wavelengths, making it easier to distinguish lesion morphology and vasculature.

The need for early detection of abnormalities that may lead to oral cancerAs physicians of the mouth, dental professionals are in a unique and important position to help protect their patients from oral cancer. In fact, dental professionals are the first line of defense against this potentially deadly disease.1

Oral Cancer Facts & Figures• Oral cancer kills roughly 1 person per hour, every hour, every day in the United States.2

• Approximately 20 million Americans are infected with HPV (human papillomavirus), of which certain strains—HPV-16 and -18— have been linked to oral cancer.2

• When found early, oral cancer patients have a 90% survival rate.2

• HPV-related oral cancer is on the rise in people under the age of 40, which is a shift from the usual risk factors of chewing tobacco, smoking, and alcohol use.2

• The CDC recommends that all patients over the age of 17 be screened annually for oral cancer.

REFERENCES: 1. Marder MZ. Ask the expert: What are the diagnostic protocols for oral cancer screenings? J Am Dent Assoc. 2001;132:83-84. 2. Oral cancer facts: rates of occurrence in the United States. Accessed at http://www.oralcancerfoundation.org/facts/index.htm on March 22, 2011.

Green-Amber Light

When suspect abnormalities are present, the Identafi® is switched to amber light, which allows the clinician to view the blood vessels around the lesions. Areas with increased diffuse and dilated vasculature are more likely to become cancerous.

Step 3

Step 1

Conventional examination of tissue is performed using Identafi®’s highly concentrated white light.

White Light

Identafi®’s patented 405-nanometer violet light enhances the fluorescence of normal healthy tissue. However, suspicious tissue appears dark and is easier to spot due to its loss of fluorescence.

Violet LightStep 2

Newly Published StudiesFebruary 2012“Early results suggest that the addition of the fluorescenceexamination at 405nm is helpful in identifying characteristicsindicative of precancer and cancer over that seen solely bycomprehensive white light examination. Images in the violetinduced autofluorescence at 405nm showed the deeperneovascularizationof the stromal changes that accompaniedthe progression to neoplasia.”

Lane P, Lam S, Follen M, MacAulay C. Oral Fluorescence Imaging Using 405-nm Excitation, Aiding the Discrimination of Cancers and Precancers by Identifying Changes in Collegan and Elastic Breakdown and Neovascularization in the Underlying Stroma. Gend Med. 2012 Feb;9(1 Suppl); S78-S82. e8

Lane P, Follen M, MacAulay C. Has Fluorescence Come of Age? A Case Series of Oral Precancers and CancersUsing White Light, Fluorescence Light at 405nm and Reflected Light at 545nm using the Trimira Identafi 3000.Gend Med. 2012 Feb:9(1 Suppl); S25-35

HSH1627

The means for early detection is now available to all front line cliniciansThe Identafi® is intended for use by dentists, hygienists and oral surgeons as an effective tool to aid in the early detection of abnormalities that may lead to oral cancer. For oral surgeons, the Identafi® can enhance the surgeon’s ability to choose biopsy sites and aid in determining the appropriate margin of surgical incision.

Identafi® Features & Benefits• Small, compact size coupled with an angled examination mirror allows users to easily inspect hard-to-reach areas, such as under the tongue, hard and soft palate, and back of pharynx

• Space-saving design fits any treatment room

• Provides real-time information

• The combination of all three multi-spectral wavelengths provides the clinician with more relevant visual information that can aid in making treatment decisions

• Avoids need for messy, bad-tasting dyes/solutions

• Expands practice offerings

• Enhances perception of practice as the “highest standard of care”

• Dental reimbursement code (D0431) available; pays for itself in as few as 8 weeks

• The only handheld intraoral device available for cancer screening

Identafi® Ordering Information:

Identafi® System Part #RT3-00371 Disposable Mirrors Part #RT3-00105(Box of 25)

Disposable Barriers Part #RT3-00415(Box of 100)

NEW!

Multi-spectral oral cancer screeningThe deep penetrating power of the Identafi® multi-spectral fluorescence and reflectance technology enhances visualization of mucosal abnormalities such as oral cancer or premalignant dysplasia that may not be apparent to the naked eye. Unlike other fluorescence technologies and dye systems, the Identafi® is multi-spectral, with three distinct color wavelengths, making it easier to distinguish lesion morphology and vasculature.

The need for early detection of abnormalities that may lead to oral cancerAs physicians of the mouth, dental professionals are in a unique and important position to help protect their patients from oral cancer. In fact, dental professionals are the first line of defense against this potentially deadly disease.1

Oral Cancer Facts & Figures• Oral cancer kills roughly 1 person per hour, every hour, every day in the United States.2

• Approximately 20 million Americans are infected with HPV (human papillomavirus), of which certain strains—HPV-16 and -18— have been linked to oral cancer.2

• When found early, oral cancer patients have a 90% survival rate.2

• HPV-related oral cancer is on the rise in people under the age of 40, which is a shift from the usual risk factors of chewing tobacco, smoking, and alcohol use.2

• The CDC recommends that all patients over the age of 17 be screened annually for oral cancer.

REFERENCES: 1. Marder MZ. Ask the expert: What are the diagnostic protocols for oral cancer screenings? J Am Dent Assoc. 2001;132:83-84. 2. Oral cancer facts: rates of occurrence in the United States. Accessed at http://www.oralcancerfoundation.org/facts/index.htm on March 22, 2011.

Green-Amber Light

When suspect abnormalities are present, the Identafi® is switched to amber light, which allows the clinician to view the blood vessels around the lesions. Areas with increased diffuse and dilated vasculature are more likely to become cancerous.

Step 3

Step 1

Conventional examination of tissue is performed using Identafi®’s highly concentrated white light.

White Light

Identafi®’s patented 405-nanometer violet light enhances the fluorescence of normal healthy tissue. However, suspicious tissue appears dark and is easier to spot due to its loss of fluorescence.

Violet LightStep 2

Newly Published StudiesFebruary 2012“Early results suggest that the addition of the fluorescenceexamination at 405nm is helpful in identifying characteristicsindicative of precancer and cancer over that seen solely bycomprehensive white light examination. Images in the violetinduced autofluorescence at 405nm showed the deeperneovascularizationof the stromal changes that accompaniedthe progression to neoplasia.”

Lane P, Lam S, Follen M, MacAulay C. Oral Fluorescence Imaging Using 405-nm Excitation, Aiding the Discrimination of Cancers and Precancers by Identifying Changes in Collegan and Elastic Breakdown and Neovascularization in the Underlying Stroma. Gend Med. 2012 Feb;9(1 Suppl); S78-S82. e8

Lane P, Follen M, MacAulay C. Has Fluorescence Come of Age? A Case Series of Oral Precancers and CancersUsing White Light, Fluorescence Light at 405nm and Reflected Light at 545nm using the Trimira Identafi 3000.Gend Med. 2012 Feb:9(1 Suppl); S25-35

Photos provided by Associate Professor Camile S Farah© 2013

LectureAdvances in optical adjunctive aids for detection and visualisation of oral cancer and mucosal pathology.

The role of the oral health professional is paramount in the early detection of mucosal disease, and there is an increasing demand on practitioners to be aware of changes in the oral cavity and to be able to deal with them accordingly.

This lecture will address new advances in the diagnosis of sinister lesions, and clearly outline strategies to deal with malignant and potentially-malignant lesions based on the latest research and clinical findings. The lecture will cover clinical features of oral cancer and potentially cancerous conditions, and update practitioners on their changing aetiology and management.

New technologies available for the early detection of sinister pathologies including diffused light illumination, tissue autofluorescence, narrow band imaging and brush biopsy will be highlighted.

Registration: 8.30am Lecture: 9.00am - 1.00pm CPD Hours: 3.5

WorkshopThis hands-on workshop will allow the participant to experience autofluorescence technology first hand under guidance.

Theoretical information delivered during lectures will be examined in more detail, and participants will undertake clinical examinations on each other. Tips for the successful use of the newest multispectral visualisation aid (Identafi™) will also be offered to aid clinicians in recognising mucosal lesions more reliably.

Discussion relating to integration of Identafi™ into clinical practice, communication with patients about the use of the device, and referral pathways will be covered in more detail.

Workshop: 1.30pm - 4.00pm CPD Hours: 2Lunch provided

Attendance at this workshop is a pre-requisite to the purchase of Identafi from Henry Schein Halas.

Your course fee will be refunded with the purchase of Identafi.

The means for early detection is now available to all front line cliniciansThe Identafi® is intended for use by dentists, hygienists and oral surgeons as an effective tool to aid in the early detection of abnormalities that may lead to oral cancer. For oral surgeons, the Identafi® can enhance the surgeon’s ability to choose biopsy sites and aid in determining the appropriate margin of surgical incision.

Identafi® Features & Benefits• Small, compact size coupled with an angled examination mirror allows users to easily inspect hard-to-reach areas, such as under the tongue, hard and soft palate, and back of pharynx

• Space-saving design fits any treatment room

• Provides real-time information

• The combination of all three multi-spectral wavelengths provides the clinician with more relevant visual information that can aid in making treatment decisions

• Avoids need for messy, bad-tasting dyes/solutions

• Expands practice offerings

• Enhances perception of practice as the “highest standard of care”

• Dental reimbursement code (D0431) available; pays for itself in as few as 8 weeks

• The only handheld intraoral device available for cancer screening

Identafi® Ordering Information:

Identafi® System Part #RT3-00371 Disposable Mirrors Part #RT3-00105(Box of 25)

Disposable Barriers Part #RT3-00415(Box of 100)

NEW!

Multi-spectral oral cancer screeningThe deep penetrating power of the Identafi® multi-spectral fluorescence and reflectance technology enhances visualization of mucosal abnormalities such as oral cancer or premalignant dysplasia that may not be apparent to the naked eye. Unlike other fluorescence technologies and dye systems, the Identafi® is multi-spectral, with three distinct color wavelengths, making it easier to distinguish lesion morphology and vasculature.

The need for early detection of abnormalities that may lead to oral cancerAs physicians of the mouth, dental professionals are in a unique and important position to help protect their patients from oral cancer. In fact, dental professionals are the first line of defense against this potentially deadly disease.1

Oral Cancer Facts & Figures• Oral cancer kills roughly 1 person per hour, every hour, every day in the United States.2

• Approximately 20 million Americans are infected with HPV (human papillomavirus), of which certain strains—HPV-16 and -18— have been linked to oral cancer.2

• When found early, oral cancer patients have a 90% survival rate.2

• HPV-related oral cancer is on the rise in people under the age of 40, which is a shift from the usual risk factors of chewing tobacco, smoking, and alcohol use.2

• The CDC recommends that all patients over the age of 17 be screened annually for oral cancer.

REFERENCES: 1. Marder MZ. Ask the expert: What are the diagnostic protocols for oral cancer screenings? J Am Dent Assoc. 2001;132:83-84. 2. Oral cancer facts: rates of occurrence in the United States. Accessed at http://www.oralcancerfoundation.org/facts/index.htm on March 22, 2011.

Green-Amber Light

When suspect abnormalities are present, the Identafi® is switched to amber light, which allows the clinician to view the blood vessels around the lesions. Areas with increased diffuse and dilated vasculature are more likely to become cancerous.

Step 3

Step 1

Conventional examination of tissue is performed using Identafi®’s highly concentrated white light.

White Light

Identafi®’s patented 405-nanometer violet light enhances the fluorescence of normal healthy tissue. However, suspicious tissue appears dark and is easier to spot due to its loss of fluorescence.

Violet LightStep 2

Newly Published StudiesFebruary 2012“Early results suggest that the addition of the fluorescenceexamination at 405nm is helpful in identifying characteristicsindicative of precancer and cancer over that seen solely bycomprehensive white light examination. Images in the violetinduced autofluorescence at 405nm showed the deeperneovascularizationof the stromal changes that accompaniedthe progression to neoplasia.”

Lane P, Lam S, Follen M, MacAulay C. Oral Fluorescence Imaging Using 405-nm Excitation, Aiding the Discrimination of Cancers and Precancers by Identifying Changes in Collegan and Elastic Breakdown and Neovascularization in the Underlying Stroma. Gend Med. 2012 Feb;9(1 Suppl); S78-S82. e8

Lane P, Follen M, MacAulay C. Has Fluorescence Come of Age? A Case Series of Oral Precancers and CancersUsing White Light, Fluorescence Light at 405nm and Reflected Light at 545nm using the Trimira Identafi 3000.Gend Med. 2012 Feb:9(1 Suppl); S25-35

Associate Professor Camile S Farah

BDSc, MDSc (OralMed OralPath), PhD, GCEd (HE), GCExLead, FRACDS (OralMed), FOMAA, FIAOO, FICD, FPFA

A/Professor Farah is a registered specialist in Oral Medicine and Oral Pathology and has interests in clinical oral medicine (mucosal pathology, salivary gland diseases, orofacial pain), diagnostic head and neck pathology (oral cancer and precancer), and oral and maxillofacial radiology (Cone Beam CT).

He maintains a private practice in Oral Medicine, is a Consultant Oral Pathologist to Qscan Radiology Clinics, Consultant in Oral Medicine & Oral Pathology at the UQ School of Dentistry, Honorary Consultant at the Head and Neck Cancer Clinic at the Royal Brisbane & Women’s Hospital, and Head of the Oral Oncology Research Program at the UQ Centre for Clinical Research (consisting of 25 staff and students), where he undertakes clinical and translational research into head and neck cancer early detection, molecular diagnostics, and imaging. He has published over 95 clinical and scientific articles including 5 book chapters, and has attracted approximately $5 million in competitive research funding.

He is a Fellow of many Academies and Honour Societies, an editorial board member for several journals, and has presented his research at many national and international meetings. He is the Immediate Inaugural Past President of the Oral Medicine Academy of Australasia, President of the Australian & New Zealand Division of the International Association for Dental Research, and Chairman of the Research Advisory Committee for the Australian Dental Research Foundation.

Photos provided by Associate Professor Camile S Farah© 2013